Epidemiologic and Molecular Prognostic Review of Glioblastoma
暂无分享,去创建一个
Jill S. Barnholtz-Sloan | John L. Villano | J. Villano | J. Barnholtz-Sloan | Q. Ostrom | C. Horbinski | Quinn T. Ostrom | Craig Horbinski | Jigisha P. Thakkar | Therese A. Dolecek | Donita D. Lightner | T. Dolecek | D. Lightner | T. A. Dolecek
[1] S. Leenstra,et al. Genetic sub‐types of human malignant astrocytoma correlate with survival , 1998, International journal of cancer.
[2] T. Holland-Letz,et al. ATRX loss refines the classification of anaplastic gliomas and identifies a subgroup of IDH mutant astrocytic tumors with better prognosis , 2013, Acta Neuropathologica.
[3] W. Curry,et al. Racial, ethnic and socioeconomic disparities in the treatment of brain tumors , 2009, Journal of Neuro-Oncology.
[4] R. Mirimanoff,et al. Radiotherapy and temozolomide for newly diagnosed glioblastoma: recursive partitioning analysis of the EORTC 26981/22981-NCIC CE3 phase III randomized trial. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[5] P. Kleihues,et al. Genetic pathways to primary and secondary glioblastoma. , 2007, The American journal of pathology.
[6] R. McLendon,et al. Altered Telomeres in Tumors with ATRX and DAXX Mutations , 2011, Science.
[7] Douglas C. Miller,et al. Preferential Inactivation of the p53 Tumor Suppressor Pathway and Lack of EGFR Amplification Distinguish de novo High Grade Pediatric Astrocytomas from de novo Adult Astrocytomas , 2000, Brain pathology.
[8] R. Mirimanoff,et al. Presence of an oligodendroglioma-like component in newly diagnosed glioblastoma identifies a pathogenetically heterogeneous subgroup and lacks prognostic value: central pathology review of the EORTC_26981/NCIC_CE.3 trial , 2012, Acta Neuropathologica.
[9] Veit Rohde,et al. EXTENT OF RESECTION AND SURVIVAL IN GLIOBLASTOMA MULTIFORME: IDENTIFICATION OF AND ADJUSTMENT FOR BIAS , 2008, Neurosurgery.
[10] Melissa Bondy,et al. Epidemiology of primary brain tumors: current concepts and review of the literature. , 2002, Neuro-oncology.
[11] Patrizia Frei,et al. Use of mobile phones and risk of brain tumours: update of Danish cohort study , 2011, BMJ : British Medical Journal.
[12] R. Wilson,et al. Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. , 2010, Cancer cell.
[13] B. Tran,et al. Survival comparison between glioblastoma multiforme and other incurable cancers , 2010, Journal of Clinical Neuroscience.
[14] H. Jürgens,et al. Pediatric high-grade astrocytomas show chromosomal imbalances distinct from adult cases. , 2001, The American journal of pathology.
[15] R. Weichselbaum,et al. Improved survival time trends for glioblastoma using the SEER 17 population-based registries , 2012, Journal of Neuro-Oncology.
[16] R. McLendon,et al. IDH1 and IDH2 mutations in gliomas. , 2009, The New England journal of medicine.
[17] G. Giles,et al. Role of medical history in brain tumour development. Results from the international adult brain tumour study , 1999, International journal of cancer.
[18] V. Beral,et al. Mobile phone use and risk of brain neoplasms and other cancers: prospective study. , 2013, International journal of epidemiology.
[19] R. Fimmers,et al. Prognostic Significance of Molecular Markers and Extent of Resection in Primary Glioblastoma Patients , 2009, Clinical Cancer Research.
[20] Z L Gokaslan,et al. A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival. , 2001, Journal of neurosurgery.
[21] D. Louis,et al. Age-Dependent Prognostic Effects of Genetic Alterations in Glioblastoma , 2004, Clinical Cancer Research.
[22] Anssi Auvinen,et al. Mobile Phone Use and Incidence of Glioma in the Nordic Countries 1979–2008: Consistency Check , 2012, Epidemiology.
[23] C. James,et al. Gene amplification as a prognostic factor in primary and secondary high-grade malignant gliomas. , 1998, International journal of oncology.
[24] Taofeek K Owonikoko,et al. Lung cancer in elderly patients: an analysis of the surveillance, epidemiology, and end results database. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[25] H. Wheeler,et al. Elderly patients aged 65–75 years with glioblastoma multiforme may benefit from long course radiation therapy with temozolomide , 2014, Journal of Neuro-Oncology.
[26] Christian HartmannBettina. Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas , 2010 .
[27] A. Falini,et al. Cancer esearch cular and Cellular Pathobiology ermal Growth Factor Receptor Expression Identifies ctionally and Molecularly Distinct Tumor-Initiating Cells uman Glioblastoma Multiforme and Is Required R Gliomagenesis , 2010 .
[28] W. Curry,et al. Racial/ethnic differences in survival among elderly patients with a primary glioblastoma , 2007, Journal of Neuro-Oncology.
[29] W. Curran,et al. Race and prognosis of brain tumor patients entering multicenter clinical trials. A report from the Radiation Therapy Oncology Group. , 1996, American journal of clinical oncology.
[30] D. Louis. WHO classification of tumours of the central nervous system , 2007 .
[31] H. Fine,et al. History of allergies and autoimmune diseases and risk of brain tumors in adults , 2002, International journal of cancer.
[32] Howard Colman,et al. MGMT promoter methylation is predictive of response to radiotherapy and prognostic in the absence of adjuvant alkylating chemotherapy for glioblastoma. , 2010, Neuro-oncology.
[33] Maria Grazia Bruzzone,et al. Methylation of O6-Methylguanine DNA Methyltransferase and Loss of Heterozygosity on 19q and/or 17p Are Overlapping Features of Secondary Glioblastomas with Prolonged Survival , 2007, Clinical Cancer Research.
[34] F. Hochberg,et al. Nonoccupational risk indicators of glioblastoma in adults , 1990, Journal of Neuro-Oncology.
[35] TERT PROMOTER MUTATIONS OCCUR FREQUENTLY IN GLIOMAS AND A SUBSET OF TUMORS DERIVED FROM CELLS WITH LOW RATES OF SELF-RENEWAL , 2014 .
[36] Guido Reifenberger,et al. Pten signaling in gliomas. , 2002, Neuro-oncology.
[37] J. Villano,et al. Clinical presentation, histology, and treatment in 430 patients with primary tumors of the spinal cord, spinal meninges, or cauda equina. , 2010, Journal of neurosurgery. Spine.
[38] Kenji Tada,et al. Prognostic value of epidermal growth factor receptor in patients with glioblastoma multiforme. , 2003, Cancer research.
[39] R. Stupp,et al. Clinical Implications of Molecular Neuropathology and Biomarkers for Malignant Glioma , 2012, Current Neurology and Neuroscience Reports.
[40] R. Fimmers,et al. Lack of prognostic relevance of alterations in the epidermal growth factor receptor-transforming growth factor-alpha pathway in human astrocytic gliomas. , 1996, Journal of neurosurgery.
[41] A. Marchetti,et al. IDH1 mutations at residue p.R132 (IDH1R132) occur frequently in high‐grade gliomas but not in other solid tumors , 2009, Human mutation.
[42] A. Verma. MGMT Gene Silencing and Benefit From Temozolomide in Glioblastoma , 2006 .
[43] P. Kleihues,et al. IDH1 Mutations as Molecular Signature and Predictive Factor of Secondary Glioblastomas , 2009, Clinical Cancer Research.
[44] Anthony Asher,et al. Survival following surgery and prognostic factors for recently diagnosed malignant glioma: data from the Glioma Outcomes Project. , 2003, Journal of neurosurgery.
[45] Susan M. Chang,et al. Prognostic factors for survival of patients with glioblastoma: recursive partitioning analysis. , 2004, Neuro-oncology.
[46] Caterina Giannini,et al. Immunohistochemical Detection of EGFRvIII in High Malignancy Grade Astrocytomas and Evaluation of Prognostic Significance , 2004, Journal of neuropathology and experimental neurology.
[47] Yuta Shibamoto,et al. Influence of extent of surgery and tumor location on treatment outcome of patients with glioblastoma multiforme treated with combined modality approach , 2005, Journal of Neuro-Oncology.
[48] Michael A. Vogelbaum,et al. Neoplasms of the central nervous system , 2015 .
[49] L. Ngo,et al. Breast cancer among the oldest old: tumor characteristics, treatment choices, and survival. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[50] R. McLendon,et al. Frequent ATRX, CIC, FUBP1 and IDH1 mutations refine the classification of malignant gliomas , 2012, Oncotarget.
[51] Faith Davis,et al. Associations of high-grade glioma with glioma risk alleles and histories of allergy and smoking. , 2011, American journal of epidemiology.
[52] Karl Schaller,et al. Long-term survival of patients with glioblastoma multiforme (GBM) , 2013, Journal of Clinical Neuroscience.
[53] H. Heinzl,et al. Anti‐O6‐Methylguanine‐Methyltransferase (MGMT) Immunohistochemistry in Glioblastoma Multiforme: Observer Variability and Lack of Association with Patient Survival Impede Its Use as Clinical Biomarker * , 2008, Brain pathology.
[54] A. Friedman,et al. Outcome and prognostic factors in adult cerebellar glioblastoma , 2013, Journal of Clinical Neuroscience.
[55] A. Sloan,et al. Patterns of care and outcomes among elderly individuals with primary malignant astrocytoma. , 2008, Journal of neurosurgery.
[56] D. Nelson,et al. Influence of location and extent of surgical resection on survival of patients with glioblastoma multiforme: results of three consecutive Radiation Therapy Oncology Group (RTOG) clinical trials. , 1993, International journal of radiation oncology, biology, physics.
[57] Daniel J Brat,et al. Genetic Markers in Glioblastoma: Prognostic Significance and Future Therapeutic Implications: On: Impact of Genotype Morphology on the Prognosis of Glioblastoma. Schmidt MC Antweiler S, Urban N, et al. J Neuropathol Exp Neurol 2002;61:321–328. , 2003, Advances in anatomic pathology.
[58] P Schaffer,et al. Descriptive epidemiology of cerebral gliomas in France , 1997, Cancer.
[59] J. Rey,et al. Allelic status of 1p and 19q in oligodendrogliomas and glioblastomas: multiplex ligation-dependent probe amplification versus loss of heterozygosity. , 2009, Cancer genetics and cytogenetics.
[60] J. Stockman,et al. Everolimus for Subependymal Giant-Cell Astrocytomas in Tuberous Sclerosis , 2012 .
[61] P. Kleihues,et al. Genetic alterations and signaling pathways in the evolution of gliomas , 2009, Cancer science.
[62] Susan M. Chang,et al. Marital status, treatment, and survival in patients with glioblastoma multiforme , 2005, Cancer.
[63] K. Hoang-Xuan,et al. Prognostic impact of molecular markers in a series of 220 primary glioblastomas , 2006, Cancer.
[64] A. Quiñones‐Hinojosa,et al. Adult cerebellar glioblastoma: understanding survival and prognostic factors using a population-based database from 1973 to 2009. , 2013, World neurosurgery.
[65] I. Petersen,et al. Association of epidermal growth factor receptor gene amplification with loss of chromosome 10 in human glioblastoma multiforme. , 1992, Journal of neurosurgery.
[66] 哲治 中川内. Silencing effect of CpG island hypermethylation and histone modifications on O6-methylguanine-DNA methyltransferase (MGMT) gene expression in human cancer , 2004 .
[67] David T. W. Jones,et al. Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma , 2012, Nature.
[68] P. Kleihues,et al. IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas. , 2009, The American journal of pathology.
[69] F. Zanella,et al. Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial. , 2006, The Lancet. Oncology.
[70] L. Hodges,et al. Prevalence of Glioblastoma Multiforme in Subjects with Prior Therapeutic Radiation , 1992, The Journal of neuroscience nursing : journal of the American Association of Neuroscience Nurses.
[71] L. Kleinberg. Polifeprosan 20, 3.85% carmustine slow-release wafer in malignant glioma: evidence for role in era of standard adjuvant temozolomide , 2012, Core evidence.
[72] M. Nikiforova,et al. Diagnostic Use of IDH1/2 Mutation Analysis in Routine Clinical Testing of Formalin-Fixed, Paraffin-Embedded Glioma Tissues , 2009, Journal of neuropathology and experimental neurology.
[73] P. Kleihues,et al. Phenotype vs Genotype in the Evolution of Astrocytic Brain Tumors , 2000, Toxicologic pathology.
[74] Andrey Korshunov,et al. Frequent ATRX mutations and loss of expression in adult diffuse astrocytic tumors carrying IDH1/IDH2 and TP53 mutations , 2012, Acta Neuropathologica.
[75] C. Horbinski. What do we know about IDH1/2 mutations so far, and how do we use it? , 2013, Acta Neuropathologica.
[76] D. Khullar,et al. The influence of regional health system characteristics on the surgical management and receipt of post operative radiation therapy for glioblastoma multiforme , 2013, Journal of Neuro-Oncology.
[77] P. Kleihues,et al. TERT promoter mutations in primary and secondary glioblastomas , 2013, Acta Neuropathologica.
[78] K. Black,et al. Comparison of survival between cerebellar and supratentorial glioblastoma patients: surveillance, epidemiology, and end results (SEER) analysis. , 2013, Neurosurgery.
[79] D. Miller,et al. Microsatellite instability occurs in distinct subtypes of pediatric but not adult central nervous system tumors. , 2001, Cancer research.
[80] P. Mckeever,et al. Primary cerebellar glioblastoma multiforme , 2004, Journal of Neuro-Oncology.
[81] S. Burma,et al. Epidermal growth factor receptor in glioma: signal transduction, neuropathology, imaging, and radioresistance. , 2010, Neoplasia.
[82] D. Haussler,et al. The Somatic Genomic Landscape of Glioblastoma , 2013, Cell.
[83] Susan M. Chang,et al. Inherited variation in immune genes and pathways and glioblastoma risk , 2010, Carcinogenesis.
[84] Christian Mawrin,et al. Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas , 2009, Acta Neuropathologica.
[85] G. Somes,et al. Racial differences in the incidence of gliomas: a retrospective study from Memphis, Tennessee. , 2002 .
[86] S. Gabriel,et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. , 2010, Cancer cell.
[87] O. Bogler,et al. A common mutant epidermal growth factor receptor confers enhanced tumorigenicity on human glioblastoma cells by increasing proliferation and reducing apoptosis. , 1996, Cancer research.
[88] N. Rothman,et al. Association between adult height, genetic susceptibility and risk of glioma. , 2012, International journal of epidemiology.
[89] T. Jiang,et al. Glioblastoma with an oligodendroglioma component: distinct clinical behavior, genetic alterations, and outcome. , 2012, Neuro-oncology.
[90] Luca Regli,et al. Clinical Trial Substantiates the Predictive Value of O-6-Methylguanine-DNA Methyltransferase Promoter Methylation in Glioblastoma Patients Treated with Temozolomide , 2004, Clinical Cancer Research.
[91] Alexander R. Pico,et al. Variants in the CDKN2B and RTEL1 regions are associated with high grade glioma susceptibility , 2009, Nature Genetics.
[92] L. Liau,et al. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate , 2009, Nature.
[93] Y. Suh,et al. Glioblastoma with oligodendroglial component represents a subgroup of glioblastoma with high prevalence of IDH1 mutation and association with younger age , 2013, Journal of Neuro-Oncology.
[94] P. Cassoni,et al. MGMT promoter hypermethylation and its associations with genetic alterations in a series of 350 brain tumors , 2012, Journal of Neuro-Oncology.
[95] Zhaoshi Jiang,et al. Evidence for sequenced molecular evolution of IDH1 mutant glioblastoma from a distinct cell of origin. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[96] W. Hall,et al. Malignant gliomas of the cerebellum: An analytic review , 1998, Journal of Neuro-Oncology.
[97] Paola Pisani,et al. Genetic Pathways to Glioblastoma , 2004, Cancer Research.
[98] Yan Ding,et al. IDH mutations predict longer survival and response to temozolomide in secondary glioblastoma , 2012, Cancer science.
[99] M. Nikiforova,et al. 1p/19q testing has no significance in the workup of glioblastomas , 2013, Neuropathology and applied neurobiology.
[100] R. Mirimanoff,et al. Outcome and prognostic factors in cerebellar glioblastoma multiforme in adults: a retrospective study from the Rare Cancer Network. , 2006, International journal of radiation oncology, biology, physics.
[101] D. Brat,et al. IDH1 mutations are common in malignant gliomas arising in adolescents: a report from the Children’s Oncology Group , 2010, Child's Nervous System.
[102] A. Auvinen,et al. An International Case-Control Study of Interleukin-4Rα, Interleukin-13, and Cyclooxygenase-2 Polymorphisms and Glioblastoma Risk , 2007, Cancer Epidemiology Biomarkers & Prevention.
[103] A. Walker,et al. Epidemiology of brain tumors , 1985, Neurology.
[104] M. Weller,et al. Geriatric neuro-oncology: from mythology to biology. , 2011, Current opinion in neurology.
[105] Y. Kondo,et al. The Global DNA Methylation Surrogate LINE-1 Methylation Is Correlated with MGMT Promoter Methylation and Is a Better Prognostic Factor for Glioma , 2011, PloS one.
[106] B. Scheithauer,et al. The 2007 WHO classification of tumours of the central nervous system , 2007, Acta Neuropathologica.
[107] K. H. Mild,et al. Case-control study of the association between malignant brain tumours diagnosed between 2007 and 2009 and mobile and cordless phone use , 2013, International journal of oncology.
[108] Elisabeth Cardis,et al. Brain tumour risk in relation to mobile telephone use: results of the INTERPHONE international case-control study. , 2010, International journal of epidemiology.
[109] R. Plunkett,et al. The impact of age and sex on the incidence of glial tumors in New York state from 1976 to 1995. , 2000, Journal of neurosurgery.
[110] M. Röösli,et al. Mobile phone use and risk of intracranial tumors: A consistency analysis , 2014, Bioelectromagnetics.
[111] P. Brastianos,et al. Prognostic and predictive value of epigenetic silencing of MGMT in patients with high grade gliomas: a systematic review and meta-analysis , 2011, Journal of Neuro-Oncology.
[112] H. Donovan,et al. Treatment disparities following the diagnosis of an astrocytoma , 2010, Journal of Neuro-Oncology.
[113] M. Wrensch,et al. Effects of antihistamine and anti‐inflammatory medication use on risk of specific glioma histologies , 2011, International journal of cancer.
[114] J. Uhm. An Integrated Genomic Analysis of Human Glioblastoma Multiforme , 2009 .
[115] W. Cavenee,et al. EGFR gene amplification ‐ rearrangement in human glioblastomas , 1995, International journal of cancer.
[116] Candace Chisolm,et al. Glioblastoma with Oligodendroglioma Component (GBM‐O): Molecular Genetic and Clinical Characteristics , 2013, Brain pathology.
[117] C. James,et al. Diversity and frequency of epidermal growth factor receptor mutations in human glioblastomas. , 2000, Cancer research.
[118] M. Iori,et al. Hypofractionated stereotactic radiation therapy for recurrent glioblastoma: single institutional experience , 2013, Radiation Oncology.
[119] D. Louis,et al. Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. , 1998, Journal of the National Cancer Institute.
[120] Didier Frappaz,et al. Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial. , 2012, The Lancet. Oncology.
[121] J. Barnholtz-Sloan,et al. CBTRUS statistical report: Primary brain and central nervous system tumors diagnosed in the United States in 2006-2010. , 2013, Neuro-oncology.
[122] D Riddoch,et al. Neoplasms of the central nervous system. , 1977, The Practitioner.
[123] Gary L. Gallia,et al. TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal , 2013, Proceedings of the National Academy of Sciences.
[124] Susan M. Chang,et al. Glioblastoma Patients Epidermal Growth Factor Receptor , and Survival in Analysis of Complex Relationships between Age , p 53 , Updated , 2001 .
[125] C. James,et al. Amplified and rearranged epidermal growth factor receptor genes in human glioblastomas reveal deletions of sequences encoding portions of the N- and/or C-terminal tails. , 1992, Proceedings of the National Academy of Sciences of the United States of America.
[126] Martin J. van den Bent,et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. , 2005, The New England journal of medicine.
[127] R. Mirimanoff,et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. , 2009, The Lancet. Oncology.
[128] S. Preston‐Martin,et al. A population‐based description of glioblastoma multiforme in Los Angeles County, 1974–1999 , 2005, Cancer.
[129] J. Abrams,et al. Patterns of care and survival for patients with glioblastoma multiforme diagnosed during 2006. , 2012, Neuro-oncology.
[130] M. Nikiforova,et al. Paradoxical Relationship Between the Degree of EGFR Amplification and Outcome in Glioblastomas , 2012, The American journal of surgical pathology.
[131] The glioblastoma multiforme in Georgia, 1977–1981 , 1985 .
[132] Dana A. Sloane. Cancer epidemiology in the United States: racial, social, and economic factors. , 2009, Methods in molecular biology.
[133] C. James,et al. PTEN mutation, EGFR amplification, and outcome in patients with anaplastic astrocytoma and glioblastoma multiforme. , 2001, Journal of the National Cancer Institute.
[134] W. Hahn,et al. Loss of ATRX, Genome Instability, and an Altered DNA Damage Response Are Hallmarks of the Alternative Lengthening of Telomeres Pathway , 2012, PLoS genetics.
[135] L. Elveback,et al. Neoplasms of the central nervous system , 1972, Neurology.
[136] Y. Yonekawa,et al. Promoter methylation of the DNA repair gene MGMT in astrocytomas is frequently associated with G:C --> A:T mutations of the TP53 tumor suppressor gene. , 2001, Carcinogenesis.
[137] J. Barnholtz-Sloan,et al. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2007-2011. , 2012, Neuro-oncology.
[138] F. Davis,et al. Conditional Survival of All Primary Brain Tumor Patients by Age, Behavior, and Histology , 2011, Neuroepidemiology.
[139] J. Buckner,et al. Conditional probability of long‐term survival in glioblastoma , 2012, Cancer.
[140] C. López-Ginés,et al. Primary glioblastomas with and without EGFR amplification: Relationship to genetic alterations and clinicopathological features , 2009, Neuropathology : official journal of the Japanese Society of Neuropathology.
[141] Gabriele Schackert,et al. Long-term survival with glioblastoma multiforme. , 2007, Brain : a journal of neurology.
[142] K. Kinzler,et al. Increased expression of the epidermal growth factor receptor gene in malignant gliomas is invariably associated with gene amplification. , 1987, Proceedings of the National Academy of Sciences of the United States of America.
[143] A. Korshunov,et al. The prognostic relevance of molecular alterations in glioblastomas for patients age < 50 years , 2005, Cancer.